pipette
ENEnglish

Estimating the Economic Burden of Typhoid Fever in Ibadan, Nigeria

Y. Yum, J. Ogundairo, F. P. Adeniji, G. Nyirenda, P. I. Udofia, S. E. Kyung, V. O. Ogunleye, M. Siribie, O. Mogeni, O. Popoola, H. Jeon, B. T. Tadesse, I. N. Okeke, F. Marks, J.-S. Lee, A. Kehinde

PreprintUso en el mundo real

En palabras de los autores

Background: Evidence on the economic burden of typhoid fever remains limited in sub-Saharan Africa. This study estimated the costs associated with typhoid fever and related invasive Salmonella infections in Ibadan, Nigeria. Methods: A field-based cost-of-illness study was conducted at six healthcare facilities between 2022 and 2025. Patients with Salmonella enterica serovar Typhi (S. Typhi), Salmonella enterica serovar Paratyphi (S. Paratyphi), invasive non-typhoidal Salmonella (iNTS), or typhoid gastrointestinal perforation (special cases) were enrolled, with malaria patients serving as controls. Direct medical, direct non-medical, and indirect costs were estimated for each episode and converted from Nigerian naira to US dollars using year-specific exchange rates for 2022-2025. Cases and controls were matched by age group, sex, and point of care, and confidence intervals were estimated using non-parametric bootstrapping. Results: Among 198 participants, 69 were S. Typhi cases, one was S. Paratyphi case, 14 were iNTS cases, 12 were special cases, and 102 were malaria controls. Average total costs per episode were 27 for S. Paratyphi, 583 for special (perforation) cases, and 309 vs. 42 (95% CI: 18-71) for S. Typhi, 560 (95% CI: 289-882) for special (perforation) cases. Conclusions: Typhoid fever imposes a considerable economic burden in Ibadan, Nigeria, particularly among patients requiring hospitalization or experiencing severe complications. These findings provide locally relevant evidence for evaluating typhoid conjugate vaccine introduction and informing resource-allocation decisions.

Resultado principalEl resumen no menciona limitaciones.

Apareció: lunes, 16 de noviembre. medRxiv. Preprint, todavía sin revisión por pares.

DOI: 10.64898/2026.11.12.26367962